Several groups have utilized GLP-1R functional endpoints as an indirect indication of the bioactivity of GLP-1 released from isolated islets
Brazilian regulator ANVISA has received at least 4 requests to licence generic semaglutide
Obtaining insurance coverage is often fraught with difficulties as many insurers reject claims for these drugs, thus exacerbating financial hurdles and potentially preventing patients from getting these transformative therapies
The findings were considered by the Pharmacovigilance Expert Advisory Group (PEAG) of the Commission on Human Medicines (CHM), which agreed with recommendations to update UK product information for all semaglutide products
Their unusual chemistry allows them to participate in redox reactions, making them of growing interest in pharmaceutical research
Today, GLP-1 drugs give millions of people new hope in their weight-loss journey, helping them achieve healthier lives and better long-term outcomes